Virbac (VIRP) H1 2025 TU earnings summary
Event summary combining transcript, slides, and related documents.
H1 2025 TU earnings summary
17 Jul, 2025Executive summary
First half 2025 revenue reached €738.3M, up 5.6% at constant exchange rates and scope year-over-year.
Second quarter revenue was €363.1M, a 6.4% increase at constant exchange rates and scope compared to Q2 2024.
Organic growth was driven by both volume (~2.1 pts) and price (~3.5 pts) increases.
Financial highlights
First half revenue grew 5.0% overall and 7.8% excluding exchange rate effects compared to H1 2024.
Sasaeah acquisition in Japan contributed 2.2 points to growth; Mopsan acquisition in Türkiye added 0.6 points.
Adjusted EBIT margin expected to remain around 16% for 2025 at constant scope.
Outlook and guidance
Revenue growth at constant exchange rates and scope projected between 4% and 6% for 2025.
Sasaeah acquisition expected to add 1 point to 2025 growth; operating income impact broadly neutral.
Cash position forecasted to improve by €80M in 2025, excluding acquisitions.
Moderate impact anticipated from potential US customs tariffs due to increased local US production.
Latest events from Virbac
- 7.9% revenue growth, 16.3% EBIT margin, and strong cash flow drive positive 2026 outlook.VIRP
H2 202518 Mar 2026 - Revenue up 15.1% and net income up 26.2% in H1 2024, driven by organic growth and acquisitions.VIRP
H1 202417 Mar 2026 - Revenue up 5.0% to €738.3M; margin down; 2025 outlook and guidance reaffirmed.VIRP
H1 20253 Feb 2026 - 2025 revenue rose 7.9% at constant rates, with 2026 growth and margin outlook boosted by acquisitions.VIRP
Q4 2025 TU19 Jan 2026 - Double-digit revenue growth and record margins driven by organic and acquisition gains.VIRP
H2 20241 Dec 2025 - Q3 revenue up 12.5% at constant rates; full-year growth guidance raised to 5.5%-7.5%.VIRP
Q3 2025 TU16 Oct 2025 - Q1 2025 revenue up 8.5% to €375.2M; 2025 growth outlook 4–6% at constant exchange rates.VIRP
Q1 2025 TU6 Jun 2025